The interaction between platelets and factor VII/VIIa.

This is a clearly written article detailing the mechanism of action of rFVIIa and its interaction with tissue factor and platelets leading to its hemostatic effect in hemophilia patients with inhibitors and those with platelet disorders. – Maadh Aldouri

Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.

This is an interesting and new case report on the occurrence of acquired factor VII deficiency in eight patients following intensive chemotherapy and/or radiotherapy followed by hematopoietic stem cell transplantation (SCT), associated with serious and sometimes fatal hemorrhagic complications with poor response to transfusion of blood components. Tests for antibodies against FVII were negative. It […]

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

This article reports 2 patients with severe thrombocytopenia and severe hemorrhage which did not respond to standard therapy and platelet transfusion, but responded quickly to administration of a single dose of rFVIIa. The first patient had Waldenstoms macroglobulinemia and immune thrombocytopenia, and the second one had acute lymphoblastic leukemia. No adverse effects for rFVIIa were […]

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Etiology of bleeding in cirrhotic patients during surgery is multifactorial, and its management includes several measures such as replacement of coagulation factors and platelets as well as the use of antifibrinolytic agents. Recombinant factor VIIa has been shown to normalize prothrombin time in patients with liver disease and to reduce transfusion requirement during OLT. In […]

Potential role for rFVIIa in transfusion medicine.

This a thorough and comprehensive review on the mechanism of action and various indications and uses of rFVIIa, highlighting the pivotal role of factor VII in hemostasis, as well as the efficacy and safety of rFVIIa. – M. Aldouri.